Abstract PS4-01-03: Cd44/pi3k/nf kappa b/ahr is a novel signaling pathway mediating breast tumor progression

Abstract Cell adhesion molecules (CAMs), present on cell surfaces, are involved in cell-to-cell and cell-extracellular adhesion. The hyaluronic acid (HA) receptor, CD44, is a CAM protein that is highly generally highly expressed in metastatic solid tumors, including breast cancer (BC), and correlates with poor prognosis. To increase our understanding of the underlying CD44-downstream signaling pathways involved in BC metastasis, we developed a tetracycline (tet)-off regulated expression of CD44s gene in BC cell line MCF-7 (B5 clone) and identified aryl hydrocarbon receptor (AHR) as a potential CD44-downstream transcriptional target by microarray analysis. To validate this observation in vitro, RNA and protein lysates collected from human metastatic BC cell lines MDA-MB-231 (expressing high levels of CD44), were examined for both CD44 and its target AHR, in the presence of HA. Our results confirmed that CD44 activation by HA significantly increased the expression of AHR at HA activation of CD44 increased significantly the expression of AHR at both mRNA and protein levels. More interestingly, inhibition of CD44 gene by its siRNA decreased significantly AHR expression, and further inhibited BC cell migration/invasion. Interestingly, pharmacological approach using inhibitors of major known transduction signaling pathways revealed that CD44 activates the transcription of AHR at least via PI3K/ Nuclear factor-kappa B (NF-κB) signaling pathway. These data support our hypothesis revealing AHR as a novel transcriptional target that underpin CD44-promoted BC cell invasion, via CD44/PI3K/AKT/ NF-κB/AHR novel signaling pathways. Citation Format: A. Ouhtit. Cd44/pi3k/nf kappa b/ahr is a novel signaling pathway mediating breast tumor progression [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS4-01-03.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-02-17
DOI
https://doi.org/10.1158/1557-3265.sabcs25-ps4-01-03
Primary Topic
Proteoglycans and glycosaminoglycans research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract PS4-01-03: Cd44/pi3k/nf kappa b/ahr is a novel signaling pathway mediating breast tumor progression

A Ouhtit
Clinical Cancer Research
Proteoglycans and glycosaminoglycans research
article

Abstract PS4-01-03: Cd44/pi3k/nf kappa b/ahr is a novel signaling pathway mediating breast tumor progression

A Ouhtit
article en

Abstract

Abstract Cell adhesion molecules (CAMs), present on cell surfaces, are involved in cell-to-cell and cell-extracellular adhesion. The hyaluronic acid (HA) receptor, CD44, is a CAM protein that is highly generally highly expressed in metastatic solid tumors, including breast cancer (BC), and correlates with poor prognosis. To increase our understanding of the underlying CD44-downstream signaling pathways involved in BC metastasis, we developed a tetracycline (tet)-off regulated expression of CD44s gene in BC cell line MCF-7 (B5 clone) and identified aryl hydrocarbon receptor (AHR) as a potential CD44-downstream transcriptional target by microarray analysis. To validate this observation in vitro, RNA and protein lysates collected from human metastatic BC cell lines MDA-MB-231 (expressing high levels of CD44), were examined for both CD44 and its target AHR, in the presence of HA. Our results confirmed that CD44 activation by HA significantly increased the expression of AHR at HA activation of CD44 increased significantly the expression of AHR at both mRNA and protein levels. More interestingly, inhibition of CD44 gene by its siRNA decreased significantly AHR expression, and further inhibited BC cell migration/invasion. Interestingly, pharmacological approach using inhibitors of major known transduction signaling pathways revealed that CD44 activates the transcription of AHR at least via PI3K/ Nuclear factor-kappa B (NF-κB) signaling pathway. These data support our hypothesis revealing AHR as a novel transcriptional target that underpin CD44-promoted BC cell invasion, via CD44/PI3K/AKT/ NF-κB/AHR novel signaling pathways. Citation Format: A. Ouhtit. Cd44/pi3k/nf kappa b/ahr is a novel signaling pathway mediating breast tumor progression [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS4-01-03.

Clinical Cancer ResearchVol. 32(4_Supplement)
American University of Iraq Sulaimani (IQ)
No poverty
Openalex Percentile: Top 55%
Proteoglycans and glycosaminoglycans research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Abstract PS4-01-03: Cd44/pi3k/nf kappa b/ahr is a novel signaling pathway mediating breast tumor progression — A Ouhtit · Clinical Cancer Research (2026) | TGRS Research Map | TGRS